BioSpace News Archive

Craig F. Walker/The Boston Globe via Getty

Vertex Gives Update on Next-in-Class CF Therapy Amid Demand for Generics

Amid growing demands for generic versions of Vertex’s Trikafta, the company provided an update on the late-stage clinical development of its next-in-class triple combination for cystic fibrosis.

February 8, 2023

·

2 min read

·

Tristan Manalac

Policy

FTC’s Non-Compete Law Could Propel Rise in Trade Secrets Lawsuits

Trade secrets litigations and disputes have been on the rise in recent years, and given the FTC’s recent proposal to ban all non-compete agreements nationwide, the trend is likely to continue.

February 8, 2023

·

5 min read

·

Rosemary Scott

Business

Do Mass Tech Layoffs Mean the Same for BioPharma?

With just under 98,000 tech employees laid off just one month into 2023, many in the life sciences are likely wondering if biotech layoffs will reach similar peaks.

February 8, 2023

·

3 min read

·

Rosemary Scott

FDA

FDA Adcomm Clears Way for GSK’s Jemperli in Rectal Cancer

The FDA’s Oncologic Drugs Advisory Committee voted 8-5 that two single-arm trials would be “sufficient to characterize the benefits and risks” of Jemperli in locally advanced rectal cancer.

February 8, 2023

·

2 min read

·

Tristan Manalac

Panel Takes on Challenges in Pain Therapeutics at BIO CEO

Tuesday, a panel of experts took on stiff questions about pain/addiction therapeutics during a panel hosted by the Biotechnology Innovation Organizaion (BIO) in NYC.

February 8, 2023

·

3 min read

·

Lisa Munger

Garuda Grabs Another $62M for Off-the-Shelf Stem Cell Therapies

Garuda Therapeutics closed a $62 million Series B round Tuesday to support its off-the-shelf, self-renewing blood stem cell technology.

February 8, 2023

·

2 min read

·

Kate Goodwin

Biotech Beach

RxSight, Inc. Announces Pricing of Public Offering of Common Stock - February 08, 2023

– RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced that it has priced its underwritten public offering.

February 8, 2023

·

4 min read

Santhera Concludes Agreement with French Authorities on Raxone® Reimbursement and Plans to Submit a Request for an Early Access Program for Vamorolone

Santhera Pharmaceuticals announces that it has secured a finalreimbursement agreement with the French authorities related to Raxone®for the treatment of Leber’s hereditary optic neuropathy and sales are expected to resume shortly.

February 8, 2023

·

4 min read

Drug Development

Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure

Sequana Medical NV announces the successful completion of its GLP animal studies, demonstrating the safety of its second-generation DSR product, following chronic exposure.

February 8, 2023

·

7 min read

Drug Development

Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®

Spexis AG announced that the Company has executed term sheets describing a clinical trial partnership with SPRIM Global Investments, a leading health sciences venture capital firm with deep industry expertise and decades of operating experience across 17 countries.

February 8, 2023

·

5 min read